![](/img/cover-not-exists.png)
Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU
Ertaş, Ragıp, Hawro, Tomasz, Altrichter, Sabine, Özyurt, Kemal, Erol, Kemal, Ketenci Ertaş, Şule, Maurer, MarcusLanguage:
english
Journal:
Allergy
DOI:
10.1111/all.14033
Date:
October, 2019
File:
PDF, 357 KB
english, 2019